ORGO
Organogenesis Holdings Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.71
+4.27%Aug 6, 2026, 20:05 UTC
Organogenesis Holdings Inc. reported its financial results for the second quarter ended June 30, 2026.
Jul 6, 2026, 20:05 UTC
Organogenesis Holdings Inc. announced that the FDA has accepted for review its Biologics License Application for ReNu, a treatment for symptomatic knee osteoarthritis.
Source:Jun 16, 2026, 00:00 UTC
Organogenesis Holdings Inc. elected Garrett Lustig, Robert Ades, Michael J. Driscoll, Prathyusha Duraibabu, and Jon Giacomin as directors effective June 15, 2026.